search 


  home about us creating value our technologies pipeline news & events

studies

  site map
   
 

NAMDRC 2009
March 26-28, 2009
Las Colinas, Texas

ISAM Congress 2009
May 10-14, 2009
Monterey, California

  PARI nebulizers are considered the gold
standard for clinical trials, and recommended in commercial sales including:

Pulmicort® (AstraZeneca)
Xopenex® (Sepracor)
TOBI® (Novartis)
Pulmozyme® (Genentech)

PARI nebulizers are the gold standard in inhalation therapy.

 

The future of effective aerosol therapies lies in the optimization of drug-to-device and device-to-drug.
PARI Pharma has taken the next step and combined formulation development, next generation aerosol platforms, and aerosol characterization under one roof.


We are currently working on formulations optimized to our Advanced Aerosol Delivery platform - eFlow®.

This multifunctional development program is the key to creating targeted therapies with high deposition amounts, low side-effect profiles, improved patient compliance…and happier, healthier patients.

After 100 years, we know aerosol science and aerosol delivery.
 

 

 

PARI Pharma Completes Successful Clinical Trials for Tobramycin 100 & Investigational eFlow for CF  [more]

- - - - - - - - - - - - - - - - -

PARI Pharma Unveils Closed System Using eFlow Technologyat Medical Plastics Conference [more]

- - - - - - - - - - - - - - - - -

Mpex Initiates a Phase 2 Clinical Trial of Aerosol MP-376 in the Treatment of Chronic Bacterial Infections in Cystic Fibrosis Patients
[more]

- - - - - - - - - - - - - - - - - 

 
     home  |  about us  |  creating value  |  our technologies  |  pipeline  |  news & events  |  studies

     © 2006-2008 PARI GmbH. All Rights Reserved.


PARI - 100 Years - Specialists in effective inhalation